{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:34:16Z","timestamp":1758944056531},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40259-017-0226-5","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T15:45:00Z","timestamp":1494517500000},"page":"275-278","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["CT-P10 (Truxima\u2122): A Rituximab Biosimilar"],"prefix":"10.1007","volume":"31","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"226_CR1","unstructured":"Celltrion Healthcare. Truxima 500\u00a0mg concentrate for solution for infusion: EU summary of product characteristics. 2017. http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1167.htm . Accessed 4 Apr 2017."},{"key":"226_CR2","unstructured":"European Medicines Agency. Assessment report: Truxima (international non-proprietary name: rituximab). 2016. http:\/\/www.ema.europa.eu . Accessed 4 Apr 2017."},{"issue":"3","key":"226_CR3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2016-209540","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Suh C-H, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):566\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"226_CR4","first-page":"2040","volume":"68","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Bozic Majstorovic L, Berrocal KA, et al. Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24\u00a0weeks [abstract no. 1635]. Arthritis Rheumatol. 2016;68(Suppl 10):2040\u20132.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 10","key":"226_CR5","first-page":"2449","volume":"67","author":"DH Yoo","year":"2015","unstructured":"Yoo DH, Park W, Suh C-H, et al. Efficacy and safety of rituximab biosimilar candidate (CT-P10) and innovator rituximab in patients with rheumatoid arthritis: results from phase I randomized controlled trial over 72 weeks [abstract no. 2058]. Arthritis. Rheumatol. 2015;67(Suppl 10):2449\u201352.","journal-title":"Rheumatol."},{"issue":"22","key":"226_CR6","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood.V128.22.1807.1807","volume":"128","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sancho J-M, Jurczak W, et al. Pharmacokinetic and safety of CT-P10, a biosimilar candidate to the rituximab reference product, in patients with newly diagnosed advanced stage follicular lymphoma (AFL) [abstract]. Blood. 2016;128(22):1807.","journal-title":"Blood"},{"key":"226_CR7","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02149121. 2017. http:\/\/www.clinicaltrials.gov . Accessed 4 Apr 2017."},{"issue":"Suppl 10","key":"226_CR8","first-page":"2067","volume":"67","author":"DH Yoo","year":"2015","unstructured":"Yoo DH, Park W, Suh C-H, et al. Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks [abstract no. 1675]. Arthritis. Rheumatol. 2015;67(Suppl 10):2067\u20139.","journal-title":"Rheumatol."},{"issue":"Suppl 2","key":"226_CR9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/annrheumdis-2016-eular.6422","volume":"75","author":"W Park","year":"2016","unstructured":"Park W, Yoo DH, Suh CH, et al. Comparable time to retreatment with CT-P10 and innovator rituximab up to 2\u00a0years in patients with active rheumatoid arthritis [abstract no. THU0162]. Ann Rheum Dis. 2016;75(Suppl 2):241\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"226_CR10","first-page":"2038","volume":"68","author":"CH Suh","year":"2016","unstructured":"Suh CH, Berrocal KA, Chalouhi E-KE, et al. Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24\u00a0weeks [abstract no. 1634]. Arthritis. Rheumatol. 2016;68(Suppl 10):2038\u201340.","journal-title":"Rheumatol."},{"key":"226_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0522-y","author":"L Gulacsi","year":"2017","unstructured":"Gulacsi L, Brodszky V, Baji P, et al. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017. doi: 10.1007\/s12325-017-0522-y .","journal-title":"Adv Ther."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0226-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0226-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0226-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T09:12:32Z","timestamp":1602061952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0226-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["226"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0226-5","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]}}}